Item 2.02 Results of Operations and Financial Condition.

On January 7, 2013, Trius Therapeutics, Inc. issued a press release presenting the balance of its cash, cash equivalents, and investments as of December 31, 2012. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 8.01 Other Events.

On January 7, 2013, Trius Therapeutics, Inc. issued a press release to announce the designation by the Food and Drug Administration of its lead investigational drug candidate, tedizolid phosphate, as a Qualified Infectious Disease Product (QIDP). A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No. Description

99.1 Trius Therapeutics, Inc. Press Release dated January 7, 2013

---